In vitro elution of amikacin from four hydrogel preparations: A pilot study.
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
OBJECTIVE: To determine in vitro elution of amikacin from poloxamer 407 NF, 1% carboxymethylcellulose (CMC), 3% CMC, 5% CMC, and control (sterile water). STUDY DESIGN: Descriptive in vitro. SAMPLE POPULATION: Triplicate samples from each experimental group. METHODS: Amikacin solution was prepared in poloxamer 407 NF, 1% CMC, 3% CMC, 5% CMC, or sterile water. Then, 1ml of phosphate-buffered saline (PBS) was added to each of three aliquots per base and the samples were incubated at 37C. PBS was removed and replaced at 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240hours and amikacin concentration was measured. RESULTS: The highest median concentration of amikacin in the eluent of poloxamer 407 NF, 3% CMC, and 5% CMC was observed at 48hours: 3300, 3030, and 2190g/ml, respectively. The highest median concentration of amikacin in the eluent of 1% CMC and sterile water were observed at 1hour: 13300 and 15600g/ml, respectively. Median eluent concentration of amikacin exceeded 2000g/ml (the reported minimum inhibitory concentration [MIC] of certain biofilm-producing methicillin-resistant Staphylococcus pseudintermedius) from 24 to 96hours for poloxamer 407 NF, 24-72hours for 3% CMC, 48-72hours for 5% CMC, 1-4hours for 1% CMC, and 1-4hours for sterile water. CONCLUSION: Amikacin elution from tested substances reached or exceeded target MIC during the 240hours tested. CLINICAL SIGNIFICANCE: Hydrogel-amikacin solutions may be useful topical treatment options for some infected wounds. In vivo safety and efficacy should be evaluated.
